term,100,150,200,250,300,350,400,450,500,550,600,650,700,750,800,850,900,950,1000,1050,1100,1150,1200,1250,1300,1350,1400,1450,1500
Toll Like Receptor 2 TLR2 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.23370670131303606,0.40851982925323316,0.28360258829621615,0.2738184928768169,0.3771011554025471,0.3049817136332997,0.3215618777670921,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.34160233416497754,0.2727309519872042,0.1483082546709326,0.09747429848778066,0.018684127694741568,-0.0,0.05999198285096348,0.15373684023411865,0.22989479564991924
Glycosphingolipid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.041415079210569195,0.056333097472084384,0.023574829307950976,0.37357913100313367,0.42053874547451886,0.3370400039892898,0.3630290710090728,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Diseases associated with the TLR signaling cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.3588456628302435,0.40851982925323316,0.3152431115359067,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.28673243841119384,0.34467707816919785
Diseases of Immune System,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.3588456628302435,0.40851982925323316,0.3152431115359067,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.28673243841119384,0.34467707816919785
Sphingolipid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.32647682367307845,0.3588456628302435,0.40851982925323316,0.28360258829621615,0.460298780269238,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4764214514527666,0.47501834589176717,0.4974262681961858,0.3947676309570099,0.29667993689032407,0.21754212784763874,0.13636814337248973,0.07124418711946415,0.16169855903876199,0.22989479564991924
Inflammasomes,-0.0,-0.0,-0.0,-0.0,-0.0,0.6801808379618418,0.45633526607489416,0.3848113214414982,0.21929709745816703,0.27542494420004743,0.34373876858833446,0.40851982925323316,0.6288471813103693,0.4960550360299878,0.4399479512586046,0.38344593397008303,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.6149511437126676,0.52072878572648,0.6108566695436696,0.6270320282248993,0.53652290205872,0.44991842921219705,0.36693715094261864,0.28732729392698947,0.3884538171863646
Toll Like Receptor TLR6:TLR2 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.23370670131303606,0.40851982925323316,0.28360258829621615,0.2738184928768169,0.3771011554025471,0.3049817136332997,0.3215618777670921,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.34160233416497754,0.2727309519872042,0.1483082546709326,0.09747429848778066,0.018684127694741568,-0.0,0.05999198285096348,0.15373684023411865,0.22989479564991924
Toll Like Receptor TLR1:TLR2 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.23370670131303606,0.40851982925323316,0.28360258829621615,0.2738184928768169,0.3771011554025471,0.3049817136332997,0.3215618777670921,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.34160233416497754,0.2727309519872042,0.1483082546709326,0.09747429848778066,0.018684127694741568,-0.0,0.05999198285096348,0.15373684023411865,0.22989479564991924
MyD88:Mal cascade initiated on plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.23370670131303606,0.40851982925323316,0.28360258829621615,0.2738184928768169,0.3771011554025471,0.3049817136332997,0.3215618777670921,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.34160233416497754,0.2727309519872042,0.1483082546709326,0.09747429848778066,0.018684127694741568,-0.0,0.05999198285096348,0.15373684023411865,0.22989479564991924
p75 NTR receptor_mediated signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.18621071960474625,0.36777483462342553,0.3049817136332997,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.15931025716879188,0.1203701826004079,0.14530181084422303,0.10312822381608998
Post_chaperonin tubulin folding pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.07802534975109535,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.6270320282248993,0.53652290205872,0.44991842921219705,0.36693715094261864,0.28732729392698947,0.3884538171863646
Nucleotide_binding domain leucine rich repeat containing receptor NLR signaling pathways,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.2709268551032968,0.10982923317772061,0.340292295269523,0.6205593477175151,0.5620625982962677,0.7224503410523735,0.6100742677258104,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.5150095925157688,0.4974262681961858,0.42994635308638907,0.3687871156527949,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.34467707816919785
Regulation of Complement cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.34373876858833446,0.40851982925323316,0.7224503410523735,0.6100742677258104,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.6108299694383924,0.52072878572648,0.6108566695436696,0.6270320282248993,0.53652290205872,0.44991842921219705,0.36693715094261864,0.28732729392698947,0.3884538171863646
Triglyceride Biosynthesis,-0.0,-0.0,-0.0,0.2746258700056286,0.8324003110589928,0.6801808379618418,0.45633526607489416,0.97851430955197,0.7379463390572966,0.5237831301355649,0.45209351219265415,0.6218975133914204,0.7224503410523735,0.6100742677258104,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.622086290316292,0.5006986114149501,0.41049888024272374,0.34160233416497754,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.35301613990991615,0.24425816619515378,0.28673243841119384,0.34467707816919785
Fatty Acyl_CoA Biosynthesis,-0.0,-0.0,0.13891519913930345,1.005725359842864,0.8324003110589928,0.6801808379618418,0.45633526607489416,1.0657254908449767,0.8550115473527862,0.6662518636109789,0.6205593477175151,0.5620625982962677,0.5657519901391357,0.460298780269238,0.42053874547451886,0.3370400039892898,0.3634846523961557,0.45196323614789524,0.3594305203634317,0.2935722257795156,0.2694939089484051,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Glutathione conjugation,-0.0,0.017534932707172296,2.2634516908872224,2.0483011393621577,1.717098441329874,1.3997535566542698,1.1274871137970612,1.0657254908449767,0.8550115473527862,0.6662518636109789,1.0078203038612978,0.816471695346362,0.7224503410523735,0.6100742677258104,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.6108566695436696,0.6270320282248993,0.53652290205872,0.44991842921219705,0.36693715094261864,0.48106236561172455,0.6581631276899017
Synthesis of very long_chain fatty acyl_CoAs,-0.0,-0.0,0.8279911773628563,2.0483011393621577,1.717098441329874,1.3997535566542698,1.1274871137970612,1.0657254908449767,0.8550115473527862,0.6662518636109789,0.6205593477175151,0.6218975133914204,0.7224503410523735,0.6100742677258104,0.5270033371919298,0.4154149024372291,0.39300215755164053,0.7067543167878418,0.5418995246735858,0.42308156825297144,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
NOD1slash2 Signaling Pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.31370024684144493,0.3399352039292808,0.2468342069634721,0.2738184928768169,0.19471906864788488,0.13809306958881637,0.10035206759719469,0.06671622006973654,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Caspase activation via extrinsic apoptotic signalig pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0066766235800495575,-0.0,-0.0,-0.0,-0.0,-0.0
Cytosolic sensors of pathogen_associated DNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulators of RIG_IslashMDA5 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MAPK targetsslash Nuclear events mediated by MAP kinases,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear Events kinase and transcription factor activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ERKslashMAPK targets,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of IRF3slashIRF7 mediated by TBK1slashIKK epsilon,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,-0.0,-0.0,-0.0,-0.0,0.24219543564612206,0.15887299732496357,0.09591583999727392,0.038632852537417384,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.05999198285096348,0.08658615095208189,0.08829645270888385
IKK complex recruitment mediated by RIP1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ligand_dependent caspase activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.030354360131868197,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
TRAF6 Mediated Induction of proinflammatory cytokines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulated Necrosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RIPK1_mediated regulated necrosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TNFR1_induced NFkappaB signaling pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TNFR1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RIG_IslashMDA5 mediated induction of IFN_alphaslashbeta pathways,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TRAF6 mediated IRF7 activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TNF signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MAP kinase activation in TLR cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MyD88 cascade initiated on plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0842184024665972,0.007458993989775186,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interleukin_1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.15700655316771536,0.1707233651426194,0.23370670131303606,0.40851982925323316,0.3152431115359067,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.24219543564612206,0.14177883725260748,0.04958778338736836,-0.0,-0.0,-0.0,-0.0,0.006011646792718298,-0.0,-0.0,-0.0,0.02195081917098921,0.22989479564991924
TRAF6 mediated NF_kB activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MAP3K8 TPL2_dependent MAPK1slash3 activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MyD88_independent TLR3slashTLR4 cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Toll Like Receptor 3 TLR3 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TRIF_mediated TLR3slashTLR4 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
activated TAK1 mediates p38 MAPK activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
JNK c_Jun kinases phosphorylation and  activation mediated by activated human TAK1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RIP_mediated NFkB activation via ZBP1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Toll Like Receptor 5 TLR5 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0842184024665972,0.007458993989775186,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Anchoring of the basal body to the plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.2738184928768169,0.1880963841772171,0.11220178449330628,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ZBP1DAI mediated induction of type I IFNs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Toll Like Receptor 9 TLR9 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MyD88 dependent cascade initiated on endosome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Toll Like Receptor 7slash8 TLR7slash8 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7slash8 or 9 activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Toll Like Receptor 10 TLR10 Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0842184024665972,0.007458993989775186,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Death Receptor Signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Fertilization,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Centrosome maturation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,-0.0,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.2173532684573593,0.1178620804183347,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RHO GTPases activate CIT,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Other semaphorin interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Semaphorin interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CRMPs in Sema3A signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sema3A PAK dependent Axon repulsion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ephrin signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EPHB_mediated forward signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EPH_Ephrin signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EPH_ephrin mediated repulsion of cells,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EPHA_mediated growth cone collapse,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RHO GTPases activate PAKs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RHO GTPases Activate ROCKs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Integrin alphaIIb beta3 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sema4D induced cell migration and growth_cone collapse,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sema4D in semaphorin signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by Robo receptor,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Myogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CDO in myogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RHO GTPases Activate WASPs and WAVEs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of actin dynamics for phagocytic cup formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Role of phospholipids in phagocytosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FCGR activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Classical antibody_mediated complement activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Platelet Aggregation Plug Formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p130Cas linkage to MAPK signaling for integrins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Recruitment of mitotic centrosome proteins and complexes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,-0.0,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.2173532684573593,0.1178620804183347,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Adherens junctions interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by EGFRvIII,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Loss of Nlp from mitotic centrosomes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.07662229221105306,0.03799490670541013,0.460298780269238,0.3804519337692116,0.3049817136332997,0.29976109115315464,0.1956126374238804,0.10927311561243283,0.04321101716224078,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Loss of proteins required for interphase microtubule organizationÂ from the centrosome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.07662229221105306,0.03799490670541013,0.460298780269238,0.3804519337692116,0.3049817136332997,0.29976109115315464,0.1956126374238804,0.10927311561243283,0.04321101716224078,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
AURKA Activation by TPX2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.06109801861232739,0.020385376178069875,0.460298780269238,0.3771011554025471,0.3049817136332997,0.274399587722287,0.19047845283066128,0.10927311561243283,0.038632852537417384,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of PLK1 Activity at G2slashM Transition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.3399352039292808,0.24370267567113504,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.25743909655495406,0.14276519814345118,0.05280040378615854,0.024995732028984658,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Polo_like kinase mediated events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cyclin AslashB1 associated events during G2slashM transition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
WNT ligand biogenesis and trafficking,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of TCF_dependent signaling by WNT ligand antagonists,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of FZD by ubiquitination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cell_cell junction organization,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.01750951263355495,0.020385376178069875,0.016590159806004097,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GRB2:SOS provides linkage to MAPK signaling for Integrins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cell junction organization,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Tight junction interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cell_extracellular matrix interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Basigin interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nephrin interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Netrin_1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of KIT signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CD209 DC_SIGN signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Rap1 signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MAP2K and MAPK activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Tie2 Signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by ERBB2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by EGFRvIII in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Degradation of GLI1 by the proteasome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of mitotic cell cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of APCslashC activators between G1slashS and early anaphase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of APCslashC and APCslashC:Cdc20 mediated degradation of mitotic proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APCslashC:Cdc20 mediated degradation of mitotic proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cdc20:Phospho_APCslashC mediated degradation of Cyclin A,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of RAS by GAPs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of NF_kappaB in B cells,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Dectin_1 mediated noncanonical NF_kB signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NIK__>noncanonical NF_kB signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GLI3 is processed to GLI3R by the proteasome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by EGFR in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Degradation of GLI2 by the proteasome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SCF_beta_TrCP mediated degradation of Emi1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Vpu mediated degradation of CD4,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CDK_mediated phosphorylation and removal of Cdc6,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ubiquitin_dependent degradation of Cyclin D1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ubiquitin_dependent degradation of Cyclin D,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of activated PAK_2p34 by proteasome mediated degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of Apoptosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Autodegradation of the E3 ubiquitin ligase COP1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Stabilization of p53,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APCslashC_mediated degradation of cell cycle proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APCslashC:Cdh1 mediated degradation of Cdc20 and other APCslashC:Cdh1 targeted proteins in late mitosisslashearly G1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APCslashC:Cdc20 mediated degradation of Securin,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Autodegradation of Cdh1 by Cdh1:APCslashC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR3 point mutants in cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR3 in disease,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FGFR2 mutant receptor activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR2 in disease,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR in disease,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR1 in disease,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FGFR1 mutant receptor activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by cytosolic FGFR1 fusion mutants,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PI3KslashAKT Signaling in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by Aberrant PI3K in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PI5P PP2A and IER3 Regulate PI3KslashAKT Signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of the PI3KslashAKT network,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CLEC7A Dectin_1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Downstream TCR signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of polyamines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hedgehog  on  state,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hedgehog  off  state,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TNFR2 non_canonical NF_kB pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Degradation of beta_catenin by the destruction complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Antigen processing_Cross presentation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ER_Phagosome pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p53_Independent DNA Damage Response,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p53_Independent G1slashS DNA damage checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CDT1 association with the CDC6:ORC:origin complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MAPK6slashMAPK4 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Asymmetric localization of PCP proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PCPslashCE pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Deactivation of the beta_catenin transactivating complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APCslashC:Cdc20 mediated degradation of Cyclin B,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phosphorylation of the APCslashC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Conversion from APCslashC:Cdc20 to APCslashC:Cdh1 in late anaphase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitotic Spindle Checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inhibition of the proteolytic activity of APCslashC required for the onset of anaphase by mitotic spindle checkpoint components,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inactivation of APCslashC via direct inhibition of the APCslashC complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
APC_Cdc20 mediated degradation of Nek2A,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of Sister Chromatid Cohesion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PTK6 Regulates RHO GTPases RAS GTPase and MAP kinases,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by PTK6,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ERBB2 Regulates Cell Motility,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PI3K events in ERBB2 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GRB2 events in ERBB2 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SHC1 events in ERBB2 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Initial triggering of complement,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by Ligand_Responsive EGFR Cancer Variants,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by Ligand_Responsive EGFR Variants in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of mRNA stability by proteins that bind AU_rich elements,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Assembly of the pre_replicative complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Vif_mediated degradation of APOBEC3G,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Orc1 removal from chromatin,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
AUF1 hnRNP D0 binds and destabilizes mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Degradation of AXIN,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Degradation of DVL,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hh mutants that don t undergo autocatalytic processing are degraded by ERAD,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hh mutants abrogate ligand secretion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hedgehog ligand biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
The role of GTSE1 in G2slashM progression after G2 checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cross_presentation of soluble exogenous antigens endosomes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of ornithine decarboxylase ODC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G1slashS DNA Damage Checkpoints,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p53_Dependent G1slashS DNA damage checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p53_Dependent G1 DNA Damage Response,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SCFSkp2_mediated degradation of p27slashp21,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cyclin A:Cdk2_associated events at S phase entry,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cyclin E associated events during G1slashS transition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of DNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA Replication Pre_Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MslashG1 Transition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of DNA replication,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Removal of licensing factors from origins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Switching of origins to a post_replicative state,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Creation of C4 and C2 activators,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Antigen activates B Cell Receptor BCR leading to generation of second messengers,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Complement cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.10993409356365073,0.09583158718368887,0.3612282167572355,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.2683842745077288,0.19284820684712395,0.4791750342508268,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
ROS RNS production in response to bacteria,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transferrin endocytosis and recycling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0842184024665972,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Iron uptake and transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.06671622006973654,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TRP channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Effects of PIP2 hydrolysis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of PC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of PA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acyl chain remodelling of PG,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acyl chain remodelling of PC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acyl chain remodelling of PE,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acyl chain remodelling of PS,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.16820536699377153,0.12847856119010595,0.10035206759719469,0.08249242906065794,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acyl chain remodelling of PI,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial Fatty Acid Beta_Oxidation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Diseases of metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.12140328891082429,0.18513620930179156,0.11527998526957496,0.05968463132853187,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defects in vitamin and cofactor metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cobalamin Cbl vitamin B12 transport and metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of water_soluble vitamins and cofactors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of folate and pterines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sulfur amino acid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of steroid hormones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Steroid hormones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Amine_derived hormones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Insulin receptor recycling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ligand_gated ion channel transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcriptional regulation of white adipocyte differentiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NODAL,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,-0.0,0.010650068958108109,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Lipoprotein metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HDL_mediated lipid transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Lipid digestion mobilization and transport,-0.0,-0.0,0.05553430445985897,-0.0,-0.0,-0.0,-0.0,-0.0,0.10690019642212098,0.1565441665171372,0.45209351219265415,0.40851982925323316,0.3612282167572355,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.25328634436646486,0.14827255586748594,0.08280646065447804,0.06742759016325087,0.042147611387854014,0.030354360131868197,0.0066766235800495575,-0.0,0.15167538296328636,0.1203701826004079,0.24109725661178752,0.30808443294338494
Hormone_sensitive lipase HSL_mediated triacylglycerol hydrolysis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.3588456628302435,0.40851982925323316,0.3612282167572355,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.27698793244689895,0.21143671073560433,0.17380349757946362,0.19148966394227257,0.18675889186971573,0.1483082546709326,0.09747429848778066,0.053184450626550854,0.018842041817493577,0.05999198285096348,0.025415916398469802,0.04290665830290516
Digestion of dietary lipid,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inositol phosphate metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of IP3 and IP4 in the cytosol,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of PIPs at the plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PI Metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of PIPs at the Golgi membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cell death signalling via NRAGE NRIF and NADE,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.3591814210137262,0.3804519337692116,0.4154149024372291,0.39300215755164053,0.6001699306496694,0.45700639597162407,0.3460509727927911,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.23410512876114725,0.15167538296328636,0.1203701826004079,0.1423411195578688,0.10312822381608998
NRAGE signals death through JNK,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.15372566065482923,0.3049817136332997,0.2856670127206264,0.1956126374238804,0.10927311561243283,0.04321101716224078,0.3018163577794321,0.2727309519872042,0.1483082546709326,0.10810383227143272,0.053184450626550854,0.018842041817493577,0.04978905895803866,0.009904075211735724,-0.0
G alpha 12slash13 signalling events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by Hippo,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.058433225574608255,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Apoptotic execution  phase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Apoptotic cleavage of cellular proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial protein import,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TGF_beta receptor signaling in EMT epithelial to mesenchymal transition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TGF_beta receptor signaling activates SMADs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.29178749412191046,0.24370267567113504,0.26953716867160166,0.18418908843527587,0.12460473870669542,0.06138916176328939,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Downregulation of TGF_beta receptor signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by BMP,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Peroxisomal lipid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Scavenging by Class A Receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis and interconversion of nucleotide di_ and triphosphates,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of porphyrins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Purine metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of nucleotides,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pyrimidine metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Complex I biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Respiratory electron transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of ATP by chemiosmotic coupling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glyoxylate metabolism and glycine degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pyruvate metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pyruvate metabolism and Citric Acid TCA cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Citric acid cycle TCA cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Histidine lysine phenylalanine tyrosine proline and tryptophan catabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial tRNA aminoacylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
tRNA Aminoacylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cytosolic tRNA aminoacylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
tRNA modification in the nucleus and cytosol,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Branched_chain amino acid catabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phase 4 _ resting membrane potential,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial translation initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial translation termination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial translation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Detoxification of Reactive Oxygen Species,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.03943825908842898,0.08532507904769875,0.023360044096676885,-0.0,0.25676311984704614,0.16718830184200817,0.09591583999727392,0.038632852537417384,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.051442697281127554,0.018599132196569397,-0.0
Cytosolic sulfonation of small molecules,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcriptional activation of mitochondrial biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucuronidation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Circadian Clock,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
BMAL1:CLOCKNPAS2 activates circadian gene expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RORA activates gene expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
YAP1_ and WWTR1 TAZ_stimulated gene expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of cholesterol biosynthesis by SREBP SREBF,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of gene expression by SREBF SREBP,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cholesterol biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear Receptor transcription pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Recycling of bile acids and salts,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Bile acid and bile salt metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of bile acids and bile salts,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of bile acids and bile salts via 7alpha_hydroxycholesterol,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of bile acids and bile salts via 27_hydroxycholesterol,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Arachidonic acid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of Leukotrienes LT and Eoxins EX,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Fatty acids,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Endogenous sterols,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cytochrome P450 _ arranged by substrate type,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phase 1 _ Functionalization of compounds,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.03943825908842898,0.08532507904769875,0.023360044096676885,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Xenobiotics,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Aflatoxin activation and detoxification,-0.0,-0.0,0.04052415623106478,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,-0.0,0.010650068958108109,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Chylomicron_mediated lipid transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of nitric oxide,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Binding and Uptake of Ligands by Scavenger Receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G_protein beta:gamma signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ca2+ pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of Kainate Receptors upon glutamate binding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Presynaptic function of Kainate receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G beta:gamma signalling through PLC beta,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Prostacyclin signalling through prostacyclin receptor,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ADP signalling through P2Y purinoceptor 12,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G_protein activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Adrenalinenoradrenaline inhibits insulin secretion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signal amplification,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ADP signalling through P2Y purinoceptor 1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Thromboxane signalling through TP receptor,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Thrombin signalling through proteinase activated receptors PARs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucagon_type ligand receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucagon_like Peptide_1 GLP1 regulates insulin secretion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of insulin secretion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Opioid Signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucagon signaling in metabolic regulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Vasopressin regulates renal water homeostasis via Aquaporins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Aquaporin_mediated transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G alpha z signalling events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GABA receptor activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Class Bslash2 Secretin family receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G beta:gamma signalling through PI3Kgamma,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of GABAB receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GPVI_mediated activation cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Scavenging of heme from plasma,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FCERI mediated Ca+2 mobilization,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CD22 mediated BCR regulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SHC_mediated cascade:FGFR4,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of Angiotensinogen to Angiotensins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of Insulin_like Growth Factor IGF transport and uptake by Insulin_like Growth Factor Binding Proteins IGFBPs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis secretion and inactivation of Glucagon_like Peptide_1 GLP_1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Incretin synthesis secretion and inactivation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis secretion and deacylation of Ghrelin,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Peptide hormone metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Insulin processing,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
VxPx cargo_targeting to cilium,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cargo trafficking to the periciliary membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
BBSome_mediated cargo_targeting to cilium,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cooperation of PDCL PhLP1 and TRiCslashCCT in G_protein beta folding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Chaperonin_mediated protein folding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Association of TriCslashCCT with target proteins during biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Prefoldin mediated transfer of substrate  to CCTslashTriC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cooperation of Prefoldin and TriCslashCCT  in actin and tubulin folding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.18513620930179156,0.11527998526957496,0.05968463132853187,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of tubulin folding intermediates by CCTslashTriC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.020385376178069875,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.27082094039495774,0.19047845283066128,0.10927311561243283,0.04321101716224078,0.024995732028984658,-0.0,0.0021198011474289477,0.2866655173358715,0.21754212784763874,0.15167538296328636,0.1203701826004079,0.15373684023411865,0.14860393718828763
Regulation of signaling by CBL,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GABA B receptor activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of G protein gated Potassium channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
eNOS activation and regulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PKA_mediated phosphorylation of CREB,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PKA activation in glucagon signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
The phototransduction cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inactivation recovery and regulation of the phototransduction cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Smooth Muscle Contraction,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Striated Muscle Contraction,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ion homeostasis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.24370267567113504,0.26953716867160166,0.1880963841772171,0.12847856119010595,0.09788656496176373,0.06671622006973654,-0.0,0.1412822139142681,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Ion transport by P_type ATPases,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.053184450626550854,0.018842041817493577,0.15577964731012384,0.16169855903876199,0.22989479564991924
Platelet calcium homeostasis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Elevation of cytosolic Ca2+ levels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Platelet homeostasis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nitric oxide stimulates guanylate cyclase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
cGMP effects,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phase 2 _ plateau phase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phase 1 _ inactivation of fast Na+ channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phase 0 _ rapid depolarisation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NCAM1 interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Class Cslash3 Metabotropic glutamateslashpheromone receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Chemokine receptors bind chemokines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nucleotide_like purinergic receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Eicosanoid ligand_binding receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Amine ligand_binding receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PKA activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G_protein mediated events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inhibition  of voltage gated Ca2+ channels via Gbetaslashgamma subunits,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PLC beta mediated events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G protein gated Potassium channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Inwardly rectifying K+ channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Potassium Channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Voltage gated Potassium channels,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of NMDA receptor upon glutamate binding and postsynaptic events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Post NMDA receptor activation events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CREB phosphorylation through the activation of Ras,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ras activation uopn Ca2+ infux through NMDA receptor,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CREB phosphorylation through the activation of CaMKII,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Unblocking of NMDA receptor glutamate binding and activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SALM protein interactions at the synapse,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phospholipase C_mediated cascade: FGFR1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phospholipase C_mediated cascade FGFR2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phospholipase C_mediated cascade FGFR3,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phospholipase C_mediated cascade FGFR4,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EGFR interacts with phospholipase C_gamma,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DAG and IP3 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PLC_gamma1 signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CaM pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Calmodulin induced events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ca_dependent events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SHC_mediated cascade:FGFR3,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SHC_mediated cascade:FGFR1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SHC_mediated cascade:FGFR2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Phosphorylation of CD3 and TCR zeta chains,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of BAD and translocation to mitochondria,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translocation of GLUT4 to the plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Metabolic Genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PI3K Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mTORC1_mediated signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PKB_mediated events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mTOR signalling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Energy dependent regulation of mTOR by LKB1_AMPK,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Macroautophagy,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PD_1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translocation of ZAP_70 to Immunological synapse,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HSF1 activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.018842041817493577,0.051442697281127554,0.018599132196569397,0.22989479564991924
Generation of second messenger molecules,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Costimulation by the CD28 family,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CD28 co_stimulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CD28 dependent PI3KslashAkt signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
VEGFR2 mediated vascular permeability,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by AKT1 E17K in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TP53 Activity through Acetylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of gene expression in beta cells,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of beta_cell development,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of innate immune responses to cytosolic DNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of BH3_only proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Intrinsic Pathway for Apoptosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Transcription of Cell Death Genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.05999198285096348,0.02195081917098921,0.015477061629520748
COPI_mediated anterograde transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
COPII Coat Protein 2 Mediated Vesicle Transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cargo concentration in the ER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Intraflagellar transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Antigen Presentation: Folding assembly and peptide loading of class I MHC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
N_glycan trimming in the ER and CalnexinslashCalreticulin cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Calnexinslashcalreticulin cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
XBP1S activates chaperone genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
IRE1alpha activates chaperones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Unfolded Protein Response UPR,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PERK regulates gene expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ATF4 activates genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
KSRP KHSRP binds and destabilizes mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Tristetraprolin TTP ZFP36 binds and destabilizes mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Butyrate Response Factor 1 BRF1 binds and destabilizes mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mRNA decay by 5  to 3  exoribonuclease,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Deadenylation_dependent mRNA decay,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Deadenylation of mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Transcription of Cell Cycle Genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
STING mediated induction of host immune responses,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Attenuation phase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.22989479564991924
Kinesins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mRNA 3 _end processing,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Vpr_mediated nuclear import of PICs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interactions of Vpr with host cellular proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Host Interactions with Influenza Factors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NS1 Mediated Effects on Host Pathways,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ISG15 antiviral mechanism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Antiviral mechanism by IFN_stimulated genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
tRNA processing in the nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cleavage of Growing Transcript in the Termination Region,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Transcription Termination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Post_Elongation Processing of the Transcript,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Post_Elongation Processing of Intron_Containing pre_mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HSF1_dependent transactivation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of Mature Transcript to Cytoplasm,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of Mature mRNA derived from an Intron_Containing Transcript,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mRNA Splicing _ Minor Pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Post_Elongation Processing of Intronless pre_mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Processing of Capped Intronless Pre_mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Processing of Intronless Pre_mRNAs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
rRNA modification in the nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Selenocysteine synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Viral mRNA Translation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Peptide chain elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of Ribonucleoproteins into the Host Nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of Glucokinase by Glucokinase Regulatory Protein,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Export of Viral Ribonucleoproteins from Nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NEPslashNS2 Interacts with the Cellular Export Machinery,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cellular response to heat stress,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of HSF1_mediated heat shock response,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SUMOylation of DNA damage response and repair proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SUMO E3 ligases SUMOylate target proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcriptional regulation by small RNAs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear Envelope Breakdown,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metabolism of non_coding RNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
snRNP Assembly,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SUMOylation of RNA binding proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hexose transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucose transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SUMOylation of DNA replication proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Viral Messenger RNA Synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of Mature mRNA Derived from an Intronless Transcript,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of Mature mRNAs Derived from Intronless Transcripts,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of the SLBP Dependant Mature mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of the SLBP independent Mature mRNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear Pore Complex NPC Disassembly,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear import of Rev protein,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interactions of Rev with host cellular proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Rev_mediated nuclear export of HIV RNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
COPI_independent Golgi_to_ER retrograde traffic,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
COPI_dependent Golgi_to_ER retrograde traffic,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Eukaryotic Translation Termination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HS_GAG biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Visual phototransduction,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Retinoid metabolism and transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.24109725661178752,0.3334455210403917
Metabolism of fat_soluble vitamins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.15373684023411865,0.3334455210403917
HS_GAG degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0410802519636159,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.05194072049486629,0.018842041817493577,0.051442697281127554,0.020649147814572097,0.015477061629520748
Diseases associated with glycosaminoglycan metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective B3GALT6 causes EDSP2 and SEMDJL1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective B4GALT7 causes EDS progeroid type,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective B3GAT3 causes JDSSDHD,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
A tetrasaccharide linker sequence is required for GAG synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Heparan sulfateslashheparin HS_GAG metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.009826492517979402,-0.0,-0.0
Chondroitin sulfateslashdermatan sulfate metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective C1GALT1C1 causes Tn polyagglutination syndrome TNPS,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Chondroitin sulfate biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Keratan sulfate biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.26953716867160166,0.1880963841772171,0.13809306958881637,0.1027507743168881,0.08249242906065794,0.02503586922163459,-0.0,-0.0,0.2727309519872042,0.17769217044403784,0.15374993020978167,0.09640472974406053,0.05869175849741947,0.05999198285096348,0.08658615095208189,0.08829645270888385
Keratan sulfateslashkeratin metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.01750951263355495,0.020385376178069875,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.27082094039495774,0.6375118398532623,0.5418995246735858,0.42308156825297144,0.3666207093414299,0.4974262681961858,0.42994635308638907,0.3687871156527949,0.27452457803132857,0.24754549526240324,0.16787359371456034,0.24109725661178752,0.3334455210403917
Diseases of glycosylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Diseases associated with O_glycosylation of proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective B3GALTL causes Peters_plus syndrome PpS,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.25376729878252624,0.2173532684573593,0.15887299732496357,0.09591583999727392,0.04321101716224078,0.016956587634047397,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
O_glycosylation of TSR domain_containing proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.12847856119010595,0.10035206759719469,0.08249242906065794,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
O_linked glycosylation of mucins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Termination of O_glycan biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.26701108107505545,0.34373876858833446,0.40851982925323316,0.28360258829621615,0.37357913100313367,0.3771011554025471,0.3049817136332997,0.25676311984704614,0.19047845283066128,0.10927311561243283,0.04321101716224078,0.024995732028984658,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective GALNT12 causes colorectal cancer 1 CRCS1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
The canonical retinoid cycle in rods twilight vision,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RA biosynthesis pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by Retinoic Acid,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ABC_family proteins mediated transport,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Miscellaneous transport and binding events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Uptake and actions of bacterial toxins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.15577964731012384,0.16169855903876199,0.22989479564991924
Dopamine Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Serotonin Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Norepinephrine Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Acetylcholine Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glutamate Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Neurotransmitter Release Cycle,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
GABA synthesis release reuptake and degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Na+slashCl_ dependent neurotransmitter transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Amine compound SLC transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of inorganic cationsslashanions and amino acidsslasholigopeptides,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.003812518794343817,0.24370267567113504,0.2602171608125759,0.16820536699377153,0.09811269996920162,0.027773562769054766,0.02898752571521649,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.005384718985412739,-0.0,-0.0,-0.0,-0.0
Amino acid transport across the plasma membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.09583158718368887,0.3612282167572355,0.460298780269238,0.3804519337692116,0.3049817136332997,0.3215618777670921,0.2683842745077288,0.19284820684712395,0.1394200312565907,0.13669465580334977,0.11269421607427325,0.06024891403647658,0.049593072797704696,0.018684127694741568,-0.0,0.009826492517979402,-0.0,-0.0
Amino acid and oligopeptide SLC transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.28360258829621615,0.3279722151162562,0.3076380544367165,0.25376729878252624,0.20372451675797737,0.1178620804183347,0.04958778338736836,-0.0,-0.0,-0.0,-0.0,0.10810383227143272,0.053184450626550854,0.018842041817493577,0.05999198285096348,0.02195081917098921,0.015477061629520748
Zinc transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Metal ion SLC transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Amino acid synthesis and interconversion transamination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transport of vitamins nucleosides and related molecules,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Disorders of transmembrane transporters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Surfactant metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ABC transporters in lipid homeostasis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis HFTC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Elastic fibre formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Retrograde transport at the Trans_Golgi_Network,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glutamate Binding Activation of AMPA Receptors and Synaptic Plasticity,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gap junction trafficking,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gap junction trafficking and regulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Golgi Associated Vesicle Biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
trans_Golgi Network Vesicle Budding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Clathrin derived vesicle budding,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Lysosome Vesicle Biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nef_mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
The role of Nef in HIV_1 replication and disease pathogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Trafficking of GluR2_containing AMPA receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Trafficking of AMPA receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
EGFR downregulation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Molecules associated with elastic fibres,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
WNT5A_dependent internalization of FZD4,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Recycling pathway of L1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
L1CAM interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interaction between L1 and Ankyrins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Biosynthesis of the N_glycan precursor dolichol lipid_linked oligosaccharide LLO and transfer to a nascent protein,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of substrates in N_glycan biosythesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sialic acid metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.1707233651426194,0.23370670131303606,0.2766353722121018,0.24370267567113504,0.26953716867160166,0.1880963841772171,0.3049817136332997,0.3215618777670921,0.27698793244689895,0.19284820684712395,0.1412822139142681,0.13669465580334977,0.11269421607427325,0.06024891403647658,0.038867494220362946,0.005384718985412739,-0.0,-0.0,-0.0,-0.0
N_Glycan antennae elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.40851982925323316,0.28360258829621615,0.37357913100313367,0.3771011554025471,0.3049817136332997,0.25676311984704614,0.19047845283066128,0.10927311561243283,0.04321101716224078,0.024995732028984658,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
N_glycan antennae elongation in the medialslashtrans_Golgi,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.40851982925323316,0.3152431115359067,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.29976109115315464,0.21684161621563236,0.14276519814345118,0.07306715817292536,0.06533376630899727,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Intra_Golgi traffic,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gap junction assembly,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.12847856119010595,0.10035206759719469,0.08249242906065794,0.02503586922163459,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Depolymerisation of the Nuclear Lamina,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Defensins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Beta defensins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ECM proteoglycans,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Integrin cell surface interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.1565441665171372,0.23370670131303606,0.20121985367562029,0.14954900612563343,0.18513620930179156,0.3771011554025471,0.3049817136332997,0.27082094039495774,0.19047845283066128,0.10927311561243283,0.038632852537417384,0.25757318141692986,0.209653873246854,0.1483082546709326,0.09747429848778066,0.018684127694741568,-0.0,0.009826492517979402,-0.0,-0.0
Syndecan interactions,-0.0,-0.0,-0.0,-0.0,-0.0,0.6007717550664724,0.4350890800016175,0.2899417416138344,0.16099641938775663,0.26701108107505545,0.34373876858833446,0.40851982925323316,0.28360258829621615,0.37357913100313367,0.3771011554025471,0.3049817136332997,0.25676311984704614,0.19047845283066128,0.10927311561243283,0.04321101716224078,0.47501834589176717,0.4974262681961858,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Non_integrin membrane_ECM interactions,-0.0,-0.0,-0.0,-0.0,-0.0,0.17352205694379447,0.013276290833823092,-0.0,-0.0,-0.0,0.10993409356365073,0.09583158718368887,0.07802534975109535,0.14462120844815768,0.09139689247390187,0.058433225574608255,0.027773562769054766,0.02898752571521649,-0.0,-0.0,0.13669465580334977,0.11269421607427325,0.06024891403647658,0.049593072797704696,0.018684127694741568,-0.0,0.009826492517979402,-0.0,-0.0
Laminin interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Assembly of collagen fibrils and other multimeric structures,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Collagen formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Collagen biosynthesis and modifying enzymes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Collagen degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.32647682367307845,0.3588456628302435,0.40851982925323316,0.3152431115359067,0.40463908006904387,0.3771011554025471,0.3049817136332997,0.39300215755164053,0.6375118398532623,0.5418995246735858,0.42308156825297144,0.3666207093414299,0.37777724731282813,0.3215203240867473,0.2866655173358715,0.21754212784763874,0.15167538296328636,0.1203701826004079,0.15373684023411865,0.14860393718828763
Activation of Matrix Metalloproteinases,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Hyaluronan metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of SMO,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Synthesis of glycosylphosphatidylinositol GPI,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Post_translational modification: synthesis of GPI_anchored proteins,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Common Pathway of Fibrin Clot Formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of Fibrin Clot Clotting Cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.34373876858833446,0.3814193796883901,0.28360258829621615,0.3279722151162562,0.3076380544367165,0.25376729878252624,0.20372451675797737,0.1178620804183347,0.04958778338736836,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Intrinsic Pathway of Fibrin Clot Formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gamma carboxylation hypusine formation and arylsulfatase activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Sphingolipid de novo biosynthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TNF receptor superfamily TNFSF members mediating non_canonical NF_kB pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TNFs bind their physiological receptors,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Eukaryotic Translation Elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nonsense Mediated Decay NMD independent of the Exon Junction Complex EJC,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Reproduction,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Growth hormone receptor signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.04958778338736836,-0.0,-0.0,-0.0,-0.0,0.10810383227143272,0.053184450626550854,0.018842041817493577,0.05999198285096348,0.16169855903876199,0.3884538171863646
Activation of ATR in response to replication stress,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of the pre_replicative complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G0 and Early G1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signal transduction by L1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RAF_independent MAPK1slash3 activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interleukin_6 family signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
IL_6_type cytokine receptor ligand interactions,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of IFNA signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Interferon alphaslashbeta signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.05999198285096348,0.018599132196569397,0.6581631276899017
Interferon gamma signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.024149438652689873,-0.0,0.08829645270888385
Prolactin receptor signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NOTCH2 Activation and Transmission of Signal to the Nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nuclear signaling by ERBB4,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NOTCH1 Intracellular Domain Regulates Transcription,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH1 in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH1 PEST Domain Mutants in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by NOTCH1 PEST Domain Mutants,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Constitutive Signaling by NOTCH1 HD Domain Mutants,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH1 HD Domain Mutants in Cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Association of licensing factors with the pre_replicative complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G1slashS_Specific Transcription,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
E2F mediated regulation of DNA replication,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Processive synthesis on the lagging strand,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TP53 Degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TP53 Activity through Methylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.042147611387854014,0.4194086318997797,0.3469609112599105,0.27452457803132857,0.18482167671748842,0.15577964731012384,0.16169855903876199,0.22989479564991924
Translesion Synthesis by POLH,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translesion synthesis by POLK,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translesion synthesis by REV1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translesion synthesis by POLI,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Termination of translesion DNA synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.18513620930179156,0.11527998526957496,0.05968463132853187,0.027773562769054766,0.02898752571521649,-0.0,-0.0,0.024995732028984658,-0.0,0.0021198011474289477,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.030354360131868197,0.0066766235800495575,-0.0,-0.0,-0.0,-0.0,-0.0
DNA Damage Bypass,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.06024891403647658,0.025723208102499,-0.0,-0.0,-0.0,-0.0,-0.0
Recognition of DNA damage by PCNA_containing replication complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gap_filling DNA repair synthesis and ligation in GG_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Dual Incision in GG_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Base Excision Repair,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of Abasic Sites AP sites,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of AP sites via the multiple_nucleotide patch replacement pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PCNA_Dependent Long Patch Base Excision Repair,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Extension of Telomeres,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Telomere C_strand Lagging Strand Synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Lagging Strand Synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA strand elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mismatch Repair,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activated NOTCH1 Transmits Signal to the Nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by NOTCH2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TP53 Activity through Phosphorylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.030354360131868197,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Misspliced GSK3beta mutants stabilize beta_catenin,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DARPP_32 events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of MAPK pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RAF activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
CTLA4 inhibitory signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Platelet sensitization by LDL,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
S33 mutants of beta_catenin aren t phosphorylated,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
S45 mutants of beta_catenin aren t phosphorylated,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
T41 mutants of beta_catenin aren t phosphorylated,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
S37 mutants of beta_catenin aren t phosphorylated,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Beta_catenin phosphorylation cascade,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pre_NOTCH Transcription and Translation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Disassembly of the destruction complex and recruitment of AXIN to the membrane,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by WNT in cancer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Spry regulation of FGF signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of FGFR4 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of FGFR3 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of FGFR2 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative regulation of FGFR1 signaling,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FGFR2 ligand binding and activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activated point mutants of FGFR2,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FGFR1 ligand binding and activation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glycolysis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gluconeogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glucose metabolism,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glycogen breakdown glycogenolysis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pre_NOTCH Expression and Processing,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pre_NOTCH Processing in Golgi,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NRIF signals cell death from the nucleus,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
p75NTR signals via NF_kB,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TRAF6 mediated induction of TAK1 complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,0.06109801861232739,0.03799490670541013,0.08532507904769875,0.023360044096676885,-0.0,0.29976109115315464,0.21684161621563236,0.14276519814345118,0.07306715817292536,0.06533376630899727,0.042147611387854014,0.030354360131868197,0.0066766235800495575,-0.0,-0.0,-0.0,-0.0,-0.0
Budding and maturation of HIV virion,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Endosomal Sorting Complex Required For Transport ESCRT,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PinkslashParkin Mediated Mitophagy,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitophagy,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Fanconi Anemia Pathway,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Oncogene Induced Senescence,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G1 Phase,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cyclin D associated events in G1,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SMAD2slashSMAD3:SMAD4 heterotrimer regulates transcription,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcriptional activity of SMAD2slashSMAD3:SMAD4 heterotrimer,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by TGF_beta Receptor Complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Downregulation of SMAD2slash3:SMAD4 transcriptional activity,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Oxygen_dependent proline hydroxylation of Hypoxia_inducible Factor Alpha,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of Hypoxia_inducible Factor HIF by oxygen,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Cellular response to hypoxia,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Glycogen synthesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Regulation of TP53 Expression and Degradation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of D_loop Structures through Synthesis_Dependent Strand Annealing SDSA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of a pool of free 40S subunits,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Transcription Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of the beta_catenin:TCF transactivating complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of anterior HOX genes in hindbrain development during early embryogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of HOX genes during differentiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
B_WICH complex positively regulates rRNA expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Positive epigenetic regulation of rRNA expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Negative epigenetic regulation of rRNA expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
NoRC negatively regulates rRNA expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Chain Elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Transcription,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Promoter Clearance,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Promoter Escape,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Transcription Termination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RMTs methylate histone arginines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HDACs deacetylate histones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PKMTs methylate histone lysines,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HDMs demethylate histones,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcriptional regulation of pluripotent stem cells,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription Termination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Chain Elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription Initiation From Type 2 Promoter,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription Initiation From Type 1 Promoter,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RHO GTPases activate PKNs,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
ERCC6 CSB and EHMT2 G9a positively regulate rRNA expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Condensation of Prophase Chromosomes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PRC2 methylates histones and DNA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of the ternary complex and subsequently the 43S complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Ribosomal scanning and start codon recognition,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Translation initiation complex formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activation of the mRNA upon binding of the cap_binding complex and eIFs and subsequent binding to 43S,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of Senescence_Associated Heterochromatin Foci SAHF,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA DamageslashTelomere Stress Induced Senescence,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Oxidative Stress Induced Senescence,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Senescence_Associated Secretory Phenotype SASP,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Amyloid fiber formation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Deposition of new CENPA_containing nucleosomes at the centromere,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nucleosome assembly,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Chromosome Maintenance,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Telomere Maintenance,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Meiotic recombination,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Meiosis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Meiotic synapsis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Packaging Of Telomere Ends,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
SIRT1 negatively regulates rRNA Expression,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Activated PKN1 stimulates transcription of AR androgen receptor regulated genes KLK2 and KLK3,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase I Promoter Opening,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA methylation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Abortive And Retractive Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of D_Loop Structures,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of Incision Complex in GG_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Transcription Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Transcription Pre_Initiation And Promoter Opening,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HIV Transcription Initiation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Pol II CTD phosphorylation and interaction with CE,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
mRNA Capping,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of TC_NER Pre_Incision Complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Dual incision in TC_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Gap_filling DNA repair synthesis and ligation in TC_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcription_Coupled Nucleotide Excision Repair TC_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Global Genome Nucleotide Excision Repair GG_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA Damage Recognition in GG_NER,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase III Transcription Initiation From Type 3 Promoter,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Processing of DNA double_strand break ends,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
G2slashM DNA damage checkpoint,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Nonhomologous End_Joining NHEJ,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Recruitment and ATM_mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
DNA Double Strand Break Response,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HDR through Single Strand Annealing SSA,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Presynaptic phase of homologous DNA pairing and strand exchange,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Homologous DNA Pairing and Strand Exchange,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HDR through Homologous Recombination HRR,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Resolution of D_loop Structures through Holliday Junction Intermediates,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Transcription Initiation And Promoter Clearance,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Promoter Escape,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II HIV Promoter Escape,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Pre_transcription Events,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA polymerase II transcribes snRNA genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
PIWI_interacting RNA piRNA biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
MicroRNA miRNA biogenesis,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
FGFR2 alternative splicing,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Signaling by FGFR2 IIIa TM,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Abortive elongation of HIV_1 transcript in the absence of Tat,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of the Early Elongation Complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of the HIV_1 Early Elongation Complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of HIV elongation complex in the absence of HIV Tat,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
RNA Polymerase II Transcription Elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of RNA Pol II elongation complex,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HIV Transcription Elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Tat_mediated elongation of the HIV_1 transcript,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Formation of HIV_1 elongation complex containing HIV_1 Tat,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pausing and recovery of Tat_mediated HIV elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Tat_mediated HIV elongation arrest and recovery,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
HIV elongation arrest and recovery,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Pausing and recovery of HIV elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Elongation arrest and recovery,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
TP53 Regulates Transcription of DNA Repair Genes,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Transcription of the HIV genome,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
Mitochondrial translation elongation,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0,-0.0
